Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery

Canadian Journal of Anesthesia

Volumn 53, Issue 8, 2006, Pages 802-809

  Karkouti, Keyvan ^a   Yau, Terrence M ^a   Riazi, Sheila ^a   Dattilo, Kathleen M ^a   Wasowicz, Marcin ^a   Meineri, Massimiliano ^a   McCluskey, Stuart A ^a   Wijeysundera, Duminda N ^a   van Rensburg, Adriaan ^a   Beattie, W Scott ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; EARLY INTERVENTION; ERYTHROCYTE COUNT; ERYTHROCYTE TRANSFUSION; FEMALE; HEART INFARCTION; HEART SURGERY; HUMAN; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POSTOPERATIVE HEMORRHAGE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; STROKE; THERAPY RESISTANCE; TREATMENT OUTCOME;

EID: 33748868658     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03022797     Document Type: Article

References (31)

1. Erber WN. Massive blood transfusion in the elective surgical setting. Transfus Apher Sci 2002; 27: 83-92.
2. Clark AD, Gordon WC, Walker ID, Tait RC. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004; 86: 120-4.
3. Loudon B, Smith MP. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation. Intern Med J 2005; 35: 463-7.
4. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005; 45: 26-34.
5. Despotis G, Avidan M, Lublin DM. Off-label use of recombinant factor VIIa concentrates after cardiac surgery. Ann Thorac Surg 2005; 80: 3-5.
6. Ernofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 1997; 113: 576-84.
7. Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH Jr. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996; 93: 2014-8.
8. Hoffman M, Monroe DM III, Roberts HR. Activated factor VII activates factors IX and X on the surface of the activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9(Suppl 1): S61-5.
9. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery (Letter). Anesth Analg 2002; 94: 1369-70.
10. Hardy JF, de Moerloose P, Samama M; Groupe d'Intérét en Hémostase Périopératoire. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anesth 2004; 51: 293-310.
11. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol 1998; 59: 65-73.
12. O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003; 43: 1711-6.
13. de Jonge E, Friederich PW, Vlasuk GP, et al. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol 2003; 10: 495-7.
14. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery. Anesthesiology 2002; 97: 215-52.
15. Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44: 1453-62.
16. Karkouti K, Wijeysundera DN, Tan TM, et al. Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery. Can J Anesth 2006; 53: 279-87.
17. Feinstein AR. Multiple logistic regression. In: Feinstein AR (Ed.). Multivariable Analysis: An Introduction. New Haven: Yale University Press; 1996: 297-330.
18. Whitlock R, Crowther MA, Ng HJ. Bleeding in cardiac surgery: its prevention and treatment - an evidence-based review. Crit Care Clin 2005; 21: 589-610.
19. Dial S, Delabays E, Albert M, et al. Hemodilution and surgical hemostasis contribute significantly to transfusion requirements in patients undergoing coronary artery bypass. J Thorac Cardiovasc Surg 2005; 130: 654-61.
20. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 111: 1037-46.
21. Hall TS, Brevetti GR, Skoultchi AJ, Sines JC, Gregory P, Spotnitz AJ. Re-exploration for hemorrhage following open heart surgery differentiation on the causes of bleeding and the impact on patient outcomes. Ann Thorac Cardiovasc Surg 2001; 7: 352-7.
22. Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. Ann Thorac Surg 2004; 78: 527-34.
23. Dacey LJ, Munoz JJ, Baribeau YR, et al. Reexploration for hemorrhage following coronary artery bypass grafting. Incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998; 133: 442-7.
24. Ryan T, Mc Carthy JF, Rady MY, et al. Early blood-stream infection after cardiopulmonary bypass: frequency rate, risk factors, and implications. Crit Care Med 1997; 25: 2009-14.
25. Unsworth-White MJ, Herriot A, Valencia O, et al. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995; 59: 664-7.
26. Leal-Noval SR, Rincon-Ferrari MD, Garcia-Curiel A, et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest 2001; 119: 1461-8.
27. Crabtree TD, Codd JE, Fraser VJ, Bailey MS, Olsen MA, Damiano RJ Jr. Multivariate analysis of risk factors for deep and superficial sternal infection after coronary artery bypass grafting at a tertiary care medical center. Semin Thorac Cardiovasc Surg 2004; 16: 53-61.
28. van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery. A randomized clinical trial. Circulation 1998; 97: 562-8.
29. Key NS. Recombinant FVIIa for intractable hemorrhage: more questions than answers (Editorial). Transfusion 2003; 43: 1649-51.
30. Roberts HR, Monroe DM III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41(Suppl 1): 101-8.
31. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95: 596-602.